Duran, E. Et Al. 2023. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry. Rheumatology and Therapy , vol.10, no.4 , 969-981.

Duran, E., Ozturk, Z. O., BİLGİN, E., BÜYÜKAŞIK, Y., DİZDAR, Ö., Yardimci, G. K., ... Farisogullari, B.(2023). Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry. Rheumatology and Therapy , vol.10, no.4, 969-981.

Duran, EMİNE Et Al. "Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry," Rheumatology and Therapy , vol.10, no.4, 969-981, 2023

Duran, EMİNE Et Al. "Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry." Rheumatology and Therapy , vol.10, no.4, pp.969-981, 2023

Duran, E. Et Al. (2023) . "Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry." Rheumatology and Therapy , vol.10, no.4, pp.969-981.

@article{article, author={EMİNE SARIYILDIZ Et Al. }, title={Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry}, journal={Rheumatology and Therapy}, year=2023, pages={969-981} }